You are here

Our science / Clinical Trials / Find a Trial / NCT00678561

Topical CP-690,550 For Chronic Plaque Psoriasis

Back to Search Print Save as PDF Bookmark Trial

NCT00678561

Last updated on October 4, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Irvine, California, 92697 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Having chronic plaque psoriasis for at least 6 months

- Able to withdraw all prior psoriasis treatments

- Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths or
other ultraviolet light sources during the study

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence of active, latent, or inadequately treated infection with Mycobacterium
tuberculosis

- Pregnant or lactating women

- Unwilling to use appropriate contraceptive methods

NCT00678561
Pfizer
Completed
Topical CP-690,550 For Chronic Plaque Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
NCT01186744
All Genders
18+
Years
Multiple Sites
Plaque Psoriasis Patients
An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria
NCT01557283
All Genders
18+
Years
Leuven,
Psoriasis
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00678210
All Genders
18+
Years
Multiple Sites
Psoriatic Arthritis, Psoriasis, Papulosquamous Skin Diseases
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists
NCT00293709
All Genders
18+
Years
Muenchen,
Topical CP-690,550 For Chronic Plaque Psoriasis
Phase 2A Randomized, Double-Blind, Vehicle-Controlled, Intra-Individual Comparison Trial Assessing Safety, Toleration, Pharmacokinetics And Pilot Efficacy Of 4 Weeks Treatment With Topical CP-690,550 In Chronic Plaque Psoriasis
Study will test effectiveness of an experimental drug applied once or twice daily to two psoriasis plaques. Requires 1 clinic visit each week for 5 weeks.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Psoriasis
  • Drug: CP-690,550
    Topical treatment once daily for 28 days
  • Drug: CP-690,550
    Topical treatment twice daily for 28 days
  • Drug: Placebo Vehicle
    Topical treatment once daily for 28 days
  • Drug: Placebo Vehicle
    Topical treatment twice daily for 28 days
  • Experimental: 2% CP-690,550 QD
    Intervention: Drug: CP-690,550
  • Experimental: 0.2% CP-690,550 QD
    Intervention: Drug: CP-690,550
  • Experimental: 0.02% CP-690,550 QD
    Intervention: Drug: CP-690,550
  • Experimental: 2% CP-690,550 BID
    Intervention: Drug: CP-690,550
  • Experimental: 0.2% CP-690,550 BID
    Intervention: Drug: CP-690,550
  • Experimental: 0.02% CP-690,550 BID
    Intervention: Drug: CP-690,550
  • Placebo Comparator: Placebo Vehicle QD
    Intervention: Drug: Placebo Vehicle
  • Placebo Comparator: Placebo Vehicle BID
    Intervention: Drug: Placebo Vehicle
Ports WC, Feldman SR, Gupta P, Tan H, Johnson TR, Bissonnette R. Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design. J Drugs Dermatol. 2015 Aug;14(8):777-84.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
81
July 2009
July 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Having chronic plaque psoriasis for at least 6 months
  • Able to withdraw all prior psoriasis treatments
  • Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths or other ultraviolet light sources during the study

Exclusion Criteria:

  • Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis
  • Pregnant or lactating women
  • Unwilling to use appropriate contraceptive methods
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT00678561
A3921038
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now